Literature DB >> 26464682

Down-regulation of microRNA152 is associated with the diagnosis and prognosis of patients with osteosarcoma.

Nai-Guo Wang1, Da-Chuan Wang1, Bing-Yi Tan1, Feng Wang1, Ze-Nong Yuan1.   

Abstract

Potential values of microRNA152 (miR-152) as a serum diagnostic and prognostic biomarker have not been determined in human osteosarcoma. By detecting the expression of miR-152 among 80 osteosarcoma patients, 20 periostitis patients and 20 healthy individuals using qRT-PCR, we aimed to explore the clinical significance of miR-152 in osteosarcoma patients. The expression of miR-152 was significantly decreased in patients with osteosarcoma compared to patients with periostitis (P<0.01) and healthy controls (P<0.01). The relationship between clinicopathologic characteristics and miR-152 was analyzed by chi-square test. The outcome indicated that miR-152 might be linked with the development of osteosarcoma. Moreover, the receiver operating characteristic (ROC) curve was performed to estimate the diagnostic value of miR-152. The result demonstrated that miR-152 might be a promising diagnostic marker of osteosarcoma with an AUC of 0.956, combing with 92.5% specificity and 96.2% sensitivity. The relationship between miR-152 and overall survival of osteosarcoma patients was analyzed by Kaplan-Meier curve and log rank test. As a result, the survival time of patients with low miR-152 expression was significantly shorter than those with high miR-152 expression (P<0.001). Then Cox regression analysis was used to estimate the prognostic value of miR-152 in osteosarcoma. The outcomes showed that low miR-152 expression (P=0.004) might be a potential independent prognostic marker for osteosarcoma patients. These findings suggested that down-regulation of miR-152 could be considered as a predictor for diagnosis and prognosis of osteosarcoma patients.

Entities:  

Keywords:  diagnosis; miR-152; osteosarcoma; prognosis

Mesh:

Substances:

Year:  2015        PMID: 26464682      PMCID: PMC4583914     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  28 in total

1.  miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma.

Authors:  Lei Chen; Qing Wang; Guo-dong Wang; Hua-song Wang; Yong Huang; Xi-ming Liu; Xian-hua Cai
Journal:  FEBS Lett       Date:  2013-03-15       Impact factor: 4.124

2.  Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma.

Authors:  Chun Zhang; Cong Yao; Haopeng Li; Guoyu Wang; Xijing He
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance.

Authors:  Yue Chen; Yongxi Song; Zhenning Wang; Zhenyu Yue; Huimian Xu; Chengzhong Xing; Zhuangkai Liu
Journal:  J Gastrointest Surg       Date:  2010-04-27       Impact factor: 3.452

4.  MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer.

Authors:  Zsuzsanna Lichner; Annika Fendler; Carol Saleh; Aurfan N Nasser; Dina Boles; Sahar Al-Haddad; Peter Kupchak; Moyez Dharsee; Paulo S Nuin; Kenneth R Evans; Klaus Jung; Carsten Stephan; Neil E Fleshner; George M Yousef
Journal:  Clin Chem       Date:  2013-08-19       Impact factor: 8.327

5.  A microRNA polycistron as a potential human oncogene.

Authors:  Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

6.  Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma.

Authors:  Angela B Y Hui; Alice Lin; Wei Xu; Levi Waldron; Bayardo Perez-Ordonez; Ilan Weinreb; Wei Shi; Jeff Bruce; Shao Hui Huang; Brian O'Sullivan; John Waldron; Patrick Gullane; Jonathan C Irish; Kelvin Chan; Fei-Fei Liu
Journal:  Clin Cancer Res       Date:  2013-03-04       Impact factor: 12.531

7.  Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.

Authors:  G Bacci; A Briccoli; M Rocca; S Ferrari; D Donati; A Longhi; F Bertoni; P Bacchini; S Giacomini; C Forni; M Manfrini; S Galletti
Journal:  Ann Oncol       Date:  2003-07       Impact factor: 32.976

8.  Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers.

Authors:  Christina U Köhler; Oleksandr Bryk; Swetlana Meier; Kerstin Lang; Peter Rozynek; Thomas Brüning; Heiko U Käfferlein
Journal:  Biochem Biophys Res Commun       Date:  2013-07-16       Impact factor: 3.575

9.  Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas.

Authors:  Eri Hiroki; Jun-Ichi Akahira; Fumihiko Suzuki; Satoru Nagase; Kiyoshi Ito; Takashi Suzuki; Hironobu Sasano; Nobuo Yaegashi
Journal:  Cancer Sci       Date:  2009-10-08       Impact factor: 6.716

Review 10.  New molecular insights into osteosarcoma targeted therapy.

Authors:  Jilong Yang; Wei Zhang
Journal:  Curr Opin Oncol       Date:  2013-07       Impact factor: 3.645

View more
  13 in total

Review 1.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

Review 2.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

3.  miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.

Authors:  Laura Pazzaglia; Chiara Novello; Amalia Conti; Serena Pollino; Piero Picci; Maria Serena Benassi
Journal:  Cell Oncol (Dordr)       Date:  2016-11-29       Impact factor: 6.730

4.  Differential expression of AURKA/PLK4 in quiescence and senescence of osteosarcoma U2OS cells.

Authors:  Xiao-Liang Xie; Hai-Xia Zhu; Yu-Mei Li; De-Ta Chen; Tian-You Fan
Journal:  Cell Cycle       Date:  2020-03-21       Impact factor: 4.534

5.  MicroRNAs as a novel class of diagnostic biomarkers for the detection of osteosarcoma: a meta-analysis.

Authors:  Hong Liu; Ping Li; Liang Chen; Chao Jian; Zonghuan Li; Aixi Yu
Journal:  Onco Targets Ther       Date:  2017-11-01       Impact factor: 4.147

6.  Screening of disorders associated with osteosarcoma by integrated network analysis.

Authors:  Yongfeng Dou; Kai Zhu; Zhaozhong Sun; Xiaopeng Geng; Qingmin Fang
Journal:  Biosci Rep       Date:  2019-05-21       Impact factor: 3.840

Review 7.  Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment.

Authors:  Lavinia Raimondi; Angela De Luca; Viviana Costa; Nicola Amodio; Valeria Carina; Daniele Bellavia; Pierfrancesco Tassone; Stefania Pagani; Milena Fini; Riccardo Alessandro; Gianluca Giavaresi
Journal:  Oncotarget       Date:  2017-08-03

8.  Evaluating the prognostic value of miR-148/152 family in cancers: based on a systemic review of observational studies.

Authors:  Fujiao Duan; Weigang Liu; Xiaoli Fu; Yajing Feng; Liping Dai; Shuli Cui; Zhenxing Yang
Journal:  Oncotarget       Date:  2017-09-11

9.  miR-30a suppresses osteosarcoma proliferation and metastasis by downregulating MEF2D expression.

Authors:  Liuxue Du; Tianpei Chen; Kai Zhao; Dong Yang
Journal:  Onco Targets Ther       Date:  2018-04-17       Impact factor: 4.147

10.  MicroRNAs with prognostic significance in osteosarcoma: a systemic review and meta-analysis.

Authors:  Dong Cheng; Xubin Qiu; Ming Zhuang; Chenlei Zhu; Hongjun Zou; Zhiwei Liu
Journal:  Oncotarget       Date:  2017-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.